Figure 3.
![EV formation throughout storage of murine platelets requires ASM. Group data show EV number (#EVs; A-B), EV size (C-D), and EV composition in terms of concentrations of LCC and VLCC chain length ceramide and S1P (E-F) for EVs from WT platelet pools stored for 1 (D1-EVs) or 5 days (D5-EVs) with or without addition of 10 μM/L of the ASM inhibitor ARC39 (D5-EVs [ARC39]) or 0.1 U/mL SM (D1-EVs [SM]), or EVs from 5 days stored platelets from Smpd1−/− mice (D5-EVs [Smpd1−/−]). Group data are depicted as medians and 25% quartiles; n = 6-18 each. *P < .05 vs D5-EVs (A,C,F) or D1-EVs (B,D,E), respectively (1-way analysis of variance and post hoc all pairwise Tukey test).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/137/5/10.1182_blood.2020005985/1/bloodbld2020005985f3.png?Expires=1722687797&Signature=4JCYoy3TYwmrnCgJPajdYzq0I3Nz6wQ~ctmtUSkVxQO052mAnBj8DmknWhc-78vMfcZYCR6tIBr0Hi7GCO3u9Yu7wp1vbcDPzw2TnfCqQVs52nGh3sRAAgSIHdOow~1D-k6boEp-oPDmBXXNHJtMugYmXUMLBxZ2WrAiMdiSz6ippmpxaZa-aOem0OnydTb2iLFFXzf5cw2ohOIsYZINIYLWQzmOPpl-RfOlLHg~i7c8NjBeiOlPUAoFk9XHpRhCIOH~Ndz30JFDPUTbHzq9riAN-iMgODNf9HlCqFpciGXwD1GTScvP8rCeKmZ8zUGBCl75GO7QeXQ8TxYnwYAitA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
EV formation throughout storage of murine platelets requires ASM. Group data show EV number (#EVs; A-B), EV size (C-D), and EV composition in terms of concentrations of LCC and VLCC chain length ceramide and S1P (E-F) for EVs from WT platelet pools stored for 1 (D1-EVs) or 5 days (D5-EVs) with or without addition of 10 μM/L of the ASM inhibitor ARC39 (D5-EVs [ARC39]) or 0.1 U/mL SM (D1-EVs [SM]), or EVs from 5 days stored platelets from Smpd1−/− mice (D5-EVs [Smpd1−/−]). Group data are depicted as medians and 25% quartiles; n = 6-18 each. *P < .05 vs D5-EVs (A,C,F) or D1-EVs (B,D,E), respectively (1-way analysis of variance and post hoc all pairwise Tukey test).